Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.97 USD
Change Today -0.04 / -1.99%
Volume 319.9K
OGXI On Other Exchanges
Symbol
Exchange
Munich
NASDAQ CM
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. - Special Call

To discuss amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial

OncoGenex Regains Rights to Custirsen from Teva

OncoGenex Pharmaceuticals, Inc. announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva. The agreement between the two parties to terminate the collaboration includes a $23.2 million payment from Teva. This payment reflects a $27 million advance reimbursement amount less $0.8 million for expenses incurred by Teva in 2015 prior to the termination date as well as a $3 million holdback amount that may be used to settle additional expenses incurred by Teva related to the continued development of custirsen as well as certain indemnity claims. One half of the then remaining balance of the holdback amount will be released to OncoGenex in October 2015 with a further half of the then remaining amount paid in January 2016. Any final remaining amount will be released in April 2016. In addition, OncoGenex will take over responsibility for all custirsen expenses, including those related to the ENSPIRIT trial, as well as manufacturing and regulatory activities for custirsen programs that were previously managed by Teva.

OncoGenex Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

OncoGenex Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $5.68 million, or $0.26 loss per share, compared to a net loss of $6.68 million, or $0.45 loss per share, for the same quarter ended December 31, 2013. Collaboration revenue was $5.65 million, compared to $8.6 million for the same quarter ended December 31, 2013. For the year, the company reported net loss of $26.24 million, or $1.45 loss per share, compared to a net loss of $31.85 million, or $2.17 loss per share, for the year ended December 31, 2013. Collaboration revenue was $27.12 million, compared to $29.88 million for the year ended December 31, 2013.

OncoGenex Pharmaceuticals, Inc. Proposes Amendment to Certificate of Incorporation

OncoGenex Pharmaceuticals, Inc. announced that at the AGM to be held on May 21, 2015, the shareholders will consider amendment to certificate of incorporation to increase authorized shares of common stock from 50,000,000 to 75,000,000.

OncoGenex Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:00 PM

OncoGenex Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Scott Daniel Cormack, Founder, Chief Executive Officer, President, Treasurer, Secretary and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $1.97 USD -0.04

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.